Jennifer Ficenec: What Happens to Blood Products After Hospitals Say No?
Jennifer Ficenec, Executive Vice President at Blood Centers of America, shared on LinkedIn:
”The Upcycling Mindset: What Happens to Blood Products After Hospitals Say No?
Blood and – any of its components – has a limited shelf life during which it is safe for transfusion.
What happens when it is no longer safe for transfusion?
We can repurpose blood and its components to be used in:
– research
– manufacturing
– lab training.
What does it mean? Researchers need live cells and blood-based components as controls or for their experiments.
Sometime we need to test the response of real human cells to new innovations such as chemical compounds, medical devise, or the plastic that is used to handle blood.
Another use is for the training of students and lab personnel on how to handle blood, and its components is essential.
At BCA, we are committed to finding “𝘭𝘪𝘧𝘦” 𝘢𝘯𝘥 “𝘱𝘶𝘳𝘱𝘰𝘴𝘦” to those blood and blood-based components we collected from donors to give more use to research and scientific manufacturing community, not just those who need blood or its components directly.
Yes collected blood is used in transfusions by patients who suffered accidents but there are also those who suffer from immune diseases, cancer and other conditions where the blood or blood-based components can be used to treat or research treatments.
Learn more about upcycled products, including LRS chambers that are available for purchase.
Follow us for more on cell therapy innovation and our commitment to patients.”
Stay updated on the emerging with Hemostasis Today.
-
Feb 28, 2026, 17:03Investing in Education, Prevention, and Lifesaving Research for a Healthier Tomorrow – AHA
-
Feb 28, 2026, 17:00Pamela Gavin: 1 in 10 Americans Live With A Rare Disease – That Is Not Rare, That Is Public Health
-
Feb 28, 2026, 16:59Thomas Rocco Jr: Exploring Agentic AI in Cardiovascular Medicine
-
Feb 28, 2026, 16:50Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease
-
Feb 28, 2026, 16:49Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
-
Feb 28, 2026, 16:46Nicolas Hulscher: Nattokinase Dissolves 84% of Amyloid Microclots In Vitro
-
Feb 28, 2026, 16:46Alfonso Tafur: Preventing Post-Hospitalization Blood Clots Using Precision Tools and Systems
-
Feb 28, 2026, 16:39Anel Karisik: Do Antidepressants Influence Swallowing Recovery After Acute Ischemic Stroke?
-
Feb 28, 2026, 16:38Akinchan Bhardwaj: Targeting SBK2 for Selective Inflammasome Resolution in Atherosclerosis